Keyphrases
Tuberous Sclerosis Complex
100%
Mouse Model
100%
Rapamycin
100%
Intermittent Dosing
100%
Antiepileptogenic
100%
Mechanistic Target of Rapamycin Inhibitor
57%
Mammalian Target of Rapamycin (mTOR)
42%
Epilepsy
42%
Drug Exposure
28%
Day off
28%
Phosphorylation
14%
Knock-in Mouse Model
14%
TSC1
14%
Postnatal Day
14%
Molecular Mechanism
14%
Immunosuppression
14%
Pathologic
14%
Glial Fibrillary Acidic Protein
14%
Dose Effect
14%
Western Blot Analysis
14%
Time Dependence
14%
Long-term Treatment
14%
Western Blot
14%
Pathogenic Mechanism
14%
Potential Side Effects
14%
Complex Patients
14%
Epileptogenesis
14%
Megalencephaly
14%
Glial Proliferation
14%
Mouse Knockout
14%
Translational Application
14%
Target of Rapamycin Pathway
14%
Dose Dependence
14%
Drug Holiday
14%
Drug Potential
14%
Pharmacology, Toxicology and Pharmaceutical Science
Mouse Model
100%
Rapamycin
100%
Mammalian Target of Rapamycin
100%
Tuberous Sclerosis
100%
Side Effect
28%
Western Blot
28%
Knockout Mouse
14%
Protein S6
14%
Epileptogenesis
14%
Alexander Disease
14%
Glial Fibrillary Acidic Protein
14%
Drug Holiday
14%
Neuroscience
Mammalian Target of Rapamycin
100%
Tuberous Sclerosis
100%
Sirolimus
100%
Western Blot
28%
Glial Fibrillary Acidic Protein
14%
Immunosuppression
14%
Epileptogenesis
14%
Alexander Disease
14%
Protein S6
14%